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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common disorders of the liver
worldwide. Recently, a correlation between thyroid dysfunction and NAFLD has been discussed. Objective of the
present study was to investigate the association between thyroid dysfunction and hepatic steatosis.
Methods: Data from 2,445 subjects (51.7 % females) aged 18 to 65 years participating in a population-based
cross-sectional study were assessed based on a standardized questionnaire and documentation of physical,
biochemical and ultrasonographic findings. After application of exclusion criteria, a total of 1,276 subjects were
included in the study collective. The influence of potential factors on the development of hepatic steatosis was
assessed using multivariate logistic regression.
Results: The prevalence of hepatic steatosis in the study collective was 27.4 % (n = 349). The serum thyroxin (TT4)
concentration in subjects with hepatic steatosis was reduced (p = 0.0004). Adjusting for age, or BMI, there was an
increased prevalence of hepatic steatosis in subjects with reduced TT4 concentrations (p = 0.0143; p = <.0001).
Conclusions: The findings of the present study confirm an association between both subclinical and clinical
hypothyroidism and hepatic steatosis
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Background
Non-alcoholic fatty liver disease (NAFLD) represents one
of the most common chronic disorders of the liver in the
Western industrialized nations [1–4]. Its prevalence world-
wide is estimated at 20 % -30 % [5–7]. NAFLD subsumes a
variety of entities ranging from simple fatty liver or hepatic
steatosis, to non-alcoholic steatohepatitis (NASH) and
cirrhosis of the liver [8–10] and is associated with the risk
of malignant degeneration to hepatocellular carcinoma
(HCC) and the increased necessity of liver transplantation
[11, 12]. A central role in the development of NAFLD has
been ascribed to the metabolic syndrome, whose main
characteristics, such as obesity, insulin resistance and/
or type-2 diabetes mellitus and dyslipidemia are closely
associated to NAFLD [8]. Not surprisingly, there is also
an association between NAFLD and cardiovascular dis-
orders [1, 2].
Increasingly, a correlation between thyroid dysfunc-
tion, especially clinical or subclinical hypothyroidism,
and NAFLD has been discussed [6, 13–16]. Hormones
synthesized in the thyroid gland play an important role
in the regulation of diverse metabolic processes. Distur-
bances in thyroid hormone concentrations may promote
hyperlipidemia and obesity, thus contributing to NAFLD
[13, 17]. Early identification of at-risk patients is import-
ant since treatment of the hypothyroidism may reduce
the risk of NAFLD and potential complications [18]. It
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was the objective of the present study to investigate the
association between thyroid dysfunction and hepatic
steatosis in an epidemiological cross-sectional study in a




A cross-sectional survey assessing the prevalence of
Echinococcus Multilocularis Infection and other medical
disorders in Leutkirch (EMIL-Study), was conducted in
Leutkirch, Germany in 2002. Initially, 4,000 of the total
12,475 residents were randomly selected by the staff of
the municipal registry office from the roster of inhabi-
tants. Out of these 4,000 persons, 107 were excluded be-
cause their address was unknown or they had not given
their informed consent. A total of 2,445 individuals fi-
nally participated in the study, corresponding to a par-
ticipation rate of 62.8 % [19]. Following exclusion of
subjects less than 18 years (n = 258) and subjects with in-
complete laboratory results (n = 230), those with past or
present hepatitis B or hepatitis C virus infections (n = 146),
hemochromatosis (n = 1) or elevated alcohol consumption
(>40 g/day in males and > 20 g/day in females; n = 69), in-
take of iodone (n = 344), antithyroid agents (n = 2) or thy-
roid hormones (n = 437), missing ultrasonographic data on
hepatic steatosis (n = 16), missing data on BMI (n = 11) or
metabolic syndrome (n = 77), a total of 1,276 subjects were
finally included in the present analysis (Fig. 1). This study
collective was then divided, based on the diagnosis of
NAFLD, into an NAFLD group (n = 349) and a healthy
control group (n = 927).
The study was conducted in accordance with the prin-
ciples of good clinical practice and the Declaration of
Helsinki. It was approved by the ethics committee of the
Medical Association of Baden-Württemberg. All partici-
pants provided written informed consent.
Examination methods and anthropometric data
Patient history, including demographics, leisure activ-
ities, past medical history, family medical history, medi-
cation history as well as nicotine and alcohol use and
nutritional habits were compiled and documented using
a standardized interview. Body height, body weight, hip,
and waist circumference were measured. The body-mass
index (BMI) and the waist-to-hip ratio (WHR) were cal-
culated according to recommendations of the World
Health Organization (WHO).
Laboratory testing
About 25 ml of whole blood was obtained from each
study participant through phlebotomy of the cubital
vein. Random glucose, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), γ-glutamyl transferase
(GGT), alkaline phosphatase (AP), C-reactive protein
(CRP), albumin, cholesterol, high density lipoprotein
(HDL), transferrin and ferritin were measured using the
Dimension XL unit (Dade Behring Inc., Newark, DE
19714, USA). Fibrinogen and coeruloplasmin were mea-
sured using the Siemens Dade Behring BII Nephelometer
(Siemens Healthcare Diagnostics GmbH; Ludwig-Erhard-
Straße 12; 65760 Eschborn, Germany). The concentration
of low density lipoprotein (LDL) was calculated using the
Friedewald formula: LDL cholesterol = total cholesterol–
HDL–(triglycerides*0.45). Thyroid-stimulating hormone
(TSH), triiodothyronine (TT3), thyroxine (TT4) and anti-
thyroid autoantibodies (Anti-TPO) were measured using
an Elecsys® 2010 Disk & Rack Analyzers (Roche Diagnos-
tics, 9115 Hague Road, Indianapolis, USA). Each param-
eter was measured twice. All assays were performed
according to the manufacturer’s recommendations. Regu-
lar precision controls were performed to assure proper
functioning of all laboratory equipment.
Criteria for thyroid dysfunction and metabolic syndrome
The diagnosis of subclinical hypothyroidism was made
in subjects with TSH concentrations ≥ 34 IU/ml and nor-
mal thyroid hormone concentrations (TT4: 12.8-20.4
pmol/l; TT3: 3.92-6.74 pmol/l). The diagnosis of clinic-
ally manifest hypothyroidism required reduced TT4 con-
centrations (<12.8 pmol/) and elevated TSH levels
(TSH ≥ 34 IU/ml).
2,445 subjects 
participated in the EMIL-study
1,276 paticipants included in the analysis
1169 excluded as followed: 
• age under 18 years
• presence of hepatitis B or C infection
• presence of haemochromatosis
• intake of iodone, antithyroid agents or      
thyroid hormones 
• excessive alcohol consumption
(men 40 g/day, women 20 g/day)
• missing values
Fig. 1 Flow of the subjects across the study. The base collective for
the present study consisted of the 2,445 subjects of the EMIL study.
Of these, 258 subjects were excluded due to age < 18 years; 69 due
to excessive alcohol consumption (>40 g/day in males and > 20 g/
day in females); 146 due to past or current hepatitis B or hepatitis C
infections;intake of iodone (n = 344), antithyroid agents (n = 2) or
thyroid hormones (n = 437); and 1 due to hemochromatosis.
Incomplete data, laboratory values or other data were also exclusion
criteria. Each box represents an exclusion criterion and contains the
corresponding number of subjects in relation to the total collective.
An individual subject may meet multiple exclusion criteria. For the
present study, the resulting collective consisted of 1,276 individuals
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Metabolic syndrome was defined according to modi-
fied U.S. National Cholesterol Education Program Adult
Treatment Panel III criteria (ATP III), whereby at least
three of the following criteria had to be met: waist cir-
cumference >102 cm in males or >88 cm females; serum
triglyceride (TG) concentration ≥ 1.7 mmol/l; serum
HDL cholesterol ≤ 1.28 mmol/l (males, 1.0 mmol/l; fe-
males, 1.3 mmol/l); history of hypertension and random
blood glucose ≥ 160 mg/dl (fasting glucose ≥ 110 mg/dl)
or confirmed diabetes mellitus [20].
Ultrasound examination and criteria for hepatic steatosis
The ultrasound examinations were performed under
standardized conditions by specially trained examiners
using four identical HDI 5000 diagnostic ultrasound
units (ALTATL Ultrasound, Philips Medical Systems,
P.O. Box 3003, Bothell, WA, USA). Unclear or patho-
logical findings were reviewed by an experienced super-
visor (>4,000 ultrasonographic examinations per year).
As far as possible, identical settings were maintained for
all units. Findings were documented using a standard-
ized recording questionnaire. Examinations included as-
sessment of the liver, gallbladder, kidneys and spleen.
The liver was assessed with respect to size, the presence
of focal lesions, and the presence of hepatic steatosis.
The diagnosis of hepatic steatosis was made based on
the basis of criteria established by Saverymuttu et al.
[21], Hamaguchi et al. [22] and Charatcharoenwitthaya
et al. [23]. The hepatic parenchyma was compared with
the renal parenchyma under consideration of the dorsal
echo attenuation, visualization of the diaphragm and
ability to assess the intrahepatic vessels. The degree of
steatosis was assigned to classes of “none” (grade 0),
“mild” (grade I), “moderate” (grade II) and “severe”
(grade III).
Statistical analysis
Statistical calculations were performed using the SAS 9.2
statistics software package (SAS Institute Inc., Cary,
North Carolina, USA). Data were first analyzed descrip-
tively. Mean and standard deviation were determined for
continuous variables. Categorical data were presented
with absolute and relative frequencies. In order to detect
differences between subjects with and without hepatic
steatosis, the Wilcoxon rank-sum test was used for con-
tinuous variables, while, for categorical variables, the χ2
test or, when the number of cases was too small, Fisher’s
exact test were used. In order to identify possible corre-
lations between thyroid hormone levels and demo-
graphic, anthropometric and biochemical parameters,
we calculated the Spearman rank correlation. In a fur-
ther analytic step, subjects were divided into four equal
groups (quartiles) on the basis of thyroid hormone con-
centrations (TSH, TT4, TT3; Table 1). The Kruskal-
Wallis test was used to identify differences between the
four groups. Bivariate and multivariate logistic regression
served to identify correlations with hepatic steatosis and
other potential risk factors. All tests were two-tailed. A




The study collective included 1,276 subjects (47.2 %, fe-
males; 52.8 %, males), whose mean age stood at 40.7 ±
12.7 years (40.0 ± 12.7 years, women; 41.3 ± 12.6 years,
men). The characteristics of the study population are
presented in Table 2. A diagnosis of hepatic steatosis
was made in 349 subjects. The prevalence of ultrasono-
graphically diagnosed hepatic steatosis was significantly
higher in males (70.8 %; n = 247) than in females
(29.2 %; n = 102; Table 2). The NAFLD group was char-
acterized by a higher BMI, WHR, arterial hypertension
and higher prevalence of metabolic syndrome according
Table 1 Breakdown of thyroid hormone parameters in quartiles
in the present study
Quartile 1 Quartile 2 Quartile 3 Quartile 4
TSH <1.0 1.01-1.49 1.50-2.18 >2.19
TT4 <74.5 74.6-83.9 84.0-94.2 >94.3
TT3 <1.40 1.41-1.57 1.58-1.81 >1.82
Table 2 Characteristics of study subjects with and without NAFLD
Variables Subjects with
NAFLD (n = 349)
Mean ± SD
Subjects without




female 102 (29.2) 500 (53.7) <.0001
male 247 (70.8) 427 (46.1)
Age 47.7 ± 11.5 38.0 ± 12.1 <.0001
BMI 29.7 ± 4.7 24.0 ± 3.7 <.0001
WHR 0.9 ± 0.1 0.8 ± 0.1 <.0001
ALT 20.9 ± 10.3 13.5 ± 5.8 <.0001
AST 11.2 ± 5.1 9.0 ± 2.6 <.0001
GGT 20.5 ± 20.6 11.0 ± 10.5 <.0001
TSH (μU/ml) 1.8 ± 1.4 1.8 ± 3.5 0.6381
TT3 (nmol/l) 1.6 ± 0.3 1.6 ± 0.3 0.3293
TT4 (nmol/l) 83.2 ± 15.6 92.0 ± 17.4 0.0004
Anti-TPO (IU/ml) 23.9 ± 72.1 23.9 ± 74.0 0.4063
Diabetes, n (%) 22 (6.3) 8 (0.9) <.0001
Metabolic syndrome, n (%) 65 (18.6) 15 (1.6) <.0001
Hypertension, n (%) 99 (28.4) 67 (7.2) <.0001
BMI = body-mass-index; WHR = waist to hip ratio; ALT = Alanine transaminase;
AST = Aspartate transaminase; GGT = Gamma-glutamyl transferase; TSH =
thyroid-stimulating hormone; TT3 = triiodothyronine; TT4 = thyroxine;
Anti-TPO = anti-thyroid autoantibodies
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to ATPIII criteria (p < 0.001). The biochemical parame-
ters ALT, AST, GGT were also significantly higher in the
group with hepatic steatosis (Table 2).
Association of NAFLD with thyroid hormone
concentrations
Hypothyroidism was diagnosed in 4.1 % (n = 52) sub-
jects. Of these, 34 subjects met criteria for subclinical,
18 for clinically manifest hypothyroidism. In the sub-
group with hepatic steatosis, 1.3 % of subjects (n = 16; 7
females, 9 males) exhibited thyroid hormone levels con-
sistent with hypothyroidism. Of these, eight subjects
(0.6 %) met criteria for subclinical, eight (0.6 %) for clin-
ically manifest hypothyroidism (Table 2). Among sub-
jects with both hepatic steatosis and elevated serum
transaminases (n = 125), six (4.8 %) exhibited thyroid
hormone levels consistent with hypothyroidism. Of
these, five subjects met criteria for subclinical, one for
clinically manifest hypothyroidism. By comparison, in
the control group, 46 subjects (25 females, 21 males) ex-
hibited reduced thyroid hormone concentrations. Of
these, 29 subjects met criteria for subclinical, 17 for clin-
ically manifest hypothyroidism. With respect to the thy-
roid hormone concentrations, there was a significant
difference only for TT4 levels (p = 0.0.0004; Table 2).
The mean values for TSH, TT3 and Anti-TPO did not
differ significantly between the groups.
In order to assess the prevalence of NAFLD, the find-
ings for TSH, TT3 and TT4 were broken down into
quartiles (Table 1) and the individual subjects analyzed.
Fig. 2 displays a downward trend in the prevalence rate
of hepatic steatosis with increasing TT4 values. By con-
trast, except in the first quartile, the prevalence rate for
hepatic steatosis showed an upward trend with increas-
ing TSH concentrations.
Association of NAFLD with other variables
Males had a 2.8-fold increased risk of NAFLD compared
with females (OR = 2.836; CI = 2.177-3.694). There was a
significant correlation between NAFLD and age (p <
0.0001). Furthermore, NAFLD shows a significant associ-
ation with BMI (p < 0.0001) and WHR (p < 0.0001). There
was also a significant correlation between the presence of
NAFLD and both metabolic syndrome (OR = 13.913;
95 % -CI 7.813 24.773; p = 0.0001) and diabetes mellitus
(OR = 7.727; 95 % -CI = 3.407-17.525; p < 0.0001).
Association of NAFLD with thyroid hormones
In the univariate analysis, TSH and TT3 show no signifi-
cant association with hepatic steatosis (p = 0.7453; p =
0.1142). For TT4 a significant correlation with NAFLD
was shown (p = 0.008; OR = 0.987; 95 % -CI = 0.979-
0.995). After adjusting for age or BMI, a significant asso-
ciation could be shown for TT4 and hepatic steatosis.
Adjusted for WHR or gender, no significant association
could detected (Table 3).
Discussion
Over the past decade, beginning with a study by Liangpun-
sakul and Chalasani in 2003 [14], the association between
thyroid dysfunction and non-alcoholic fatty liver disease
(NAFLD) has increasingly become a focus of research. After
some controversial reports [24, 25], numerous studies have
confirmed an association between thyroid function and
NAFLD [13, 15, 26, 27]. Unfortunately, most studies have
been characterized by either a relatively small or selected
study collective, or by a gender imbalance [6, 14, 15, 28–30].
In addition, study subjects were in many cases patients ra-
ther than being a collective representative of the general
population [14, 29, 30]. By contrast, the present study, like
those of Chung et al., Ittermann et al. und Zhang et al., is
characterized by a balanced gender distribution and its large
study collective representative of the general population [13,
27, 31]. In addition, with a mean age of 40.7 ± 12.7 years,
our collective is one of the younger populations studied, and
includes the age group with the highest prevalence of
NAFLD [5, 6].
The findings of the present study agree in general with
those reported from the cross-sectional study of Itter-
mann et al. In both studies, a significant inverse associ-
ation between the FT4 concentration of NAFLD could
be demonstrated, while no significant association could
be identified for TT3 or TSH [31]. This underscores the
importance of the TT4 or FT4 concentration as a
marker for hepatic steatosis in the general population.
By contrast, the TT3 concentration, both in the present
study and in those of Ittermann et al. and Xu et al., had
no identified value as a marker [6, 31]. This finding
could related to an inhibition of the conversion of TT4
to TT3, possibly explaining the subordinate diagnostic
role of the TT3 or FT3. Even the study of Chung et al.,
which presented clear evidence of the association be-
tween hypothyroidism and NAFLD, did not ascribe any
diagnostic value to the TT3 concentration [13].
Beside the inverse association with FT4, Chung et al.
and Xu et al. identified a positive association between
NAFLD and TSH [6, 13]. This association was observed
in other studies [28, 29]. The difference between these
studies and the present investigation may be the result
of a divergent classification of study subjects regarding
thyroid function or differences in recruitment of subjects
from population-based sources or from a patient collect-
ive. Data reported by Carulli et al. and Pagadala et al.
suggest, in addition, that the TSH concentration is asso-
ciated with the severity of the hepatic steatosis [15, 28].
The above observations point to a possible correlation
between thyroid dysfunction and NAFLD. This correlation
may be explained, on the one hand, by a significant
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association between thyroid dysfunction, a hypothyroid
metabolic state and the metabolic syndrome [28, 32, 33].
Metabolic syndrome, in turn, is associated with NAFLD
[1, 7, 9] and would point indirectly to a possible correlation
between thyroid dysfunction and NAFLD. On the other
hand, the correlation may be grounded in the association of
reduced TT4 levels with hypertriglyceridemia and over-
weight. Beside studies which confirm the association be-
tween thyroid dysfunction, especially the hypothyroid
metabolic state, and metabolic syndrome, there are studies
with controversial findings [34, 35]. These studies highlight
the correlation between NAFLD and thyroid dysfunction.
For example, the study by Roos et al. shows a correlation
between the FT4 level and triglycerides [33]. Our study
would confirm this finding, as our data show a significant
association between the TT4 level and triglycerides (p =
0.0027). These observations agree with the findings of other
studies that suggest a correlation between hypothyroidism
and hyperlipidemia [33, 36]. The increase in triglycerides in
patients with hypothyroidism is explained by the reduced
hepatic activity of triglyceride lipase [32, 33] and increased
fatty acid oxidation. Loria et al. come to the conclusion
that hepatic steatosis may develop from hypothyroidism-
induced hyperlipidemia and overweight [17]. The develop-
ment of hepatic steatosis may be explained by an increase
influx of triglycerides and an imbalance between the in-
and outflow of other lipids in the liver.
Because thyroid dysfunction, especially the hypothyroid
metabolic state, affects the overall metabolism and may
contribute to the development of hepatic steatosis and
more serious forms of NAFLD, future interventional stud-
ies, similar to that of Ineck et al. should focus on treat-
ment of thyroid dysfunction [18].
The present study has some limitations. Because of
the choice of study design, it was possible to investigate
associations but not causalities. While liver biopsy repre-
sents the gold standard for diagnosis of NAFLD [1], the
diagnosis of hepatic steatosis in our study was made
using ultrasonography. Also, because serum insulin
levels were not determined in fasting subjects and thus
could not be used, insulin resistance was not assessed in
this study as a possible factor impacting the association
between thyroid dysfunction and NAFLD.
Conclusions
In summary, the results of the present study agree in
many points with the findings of numerous publications
and confirm a correlation between low TT4 concentra-
tions and hepatic steatosis in a study collective represen-
tative of the general population. The prevalence of
hepatic steatosis rises significantly with reductions in
TT4 concentrations. A low TT4 concentration appears
to be an independent risk factor for hepatic steatosis.
Future studies should further elucidate the impact of
thyroid hormone parameters on NAFLD. This could
Table 3 Association of hepatic steatosis with thyroid hormone
OR (95 % -CI) p-value
bivariate
TSH 0.992 (0.945-1.042) 0.7453
TT3 0.738 (0.506-1.076) 0.1142
TT4 0.987 (0.979-0.995) 0.0008
multivariate
TT4 adjusted for age 0.990 (0.982-0.998) 0.0143
TT4 adjusted for BMI 0.988 (0.979-0.997) <.0001
TT4 adjusted for WHR 0.997 (0.987-1.006) 0.5048
TT4 Adjusted for gender 0.994 (0.985-1.002) 0.1172
TT4 Adjusted for BMI, age, WHR, gender 0.994 (0.984-1.005) 0.2959
TSH = thyroid-stimulating hormone; TT3 = triiodothyronine; TT4 = thyroxine;































Fig. 2 Prevalence of non-alcoholic fatty liver disease (NAFLD) in relation to thyroid function in the present study. The figure plots the thyroid
hormone concentrations in their respective quartiles (x-axis) against NAFLD prevalence rates in percent (y-axis). NAFLD prevalence rates show a
downward trend with increasing TT4 concentrations. In addition, a positive trend is also seen for NAFLD prevalence rates with increasing TSH
levels in the first quartile
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serve to clarify the underlying pathogenetic mechanisms
and provide potentially important data for therapeutic
and preventive measures.
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